This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales. That's why other drugmakers want to dip their toes in this lucrative and high-growth market.AbbVie (NYSE: ABBV) is one of them. The company, best known for its work in immunology, recently made a move to enter the weight loss space. Does that make AbbVie stock a buy today?Developing therapies from scratch is risky and time-consuming. That's why pharmaceutical giants often partner with small companies that already have candidates in early-stage studies -- it helps speed up the process from their perspective. AbbVie is doing just that to join the weight loss market. The company entered into an agreement with Gubra A/S, a Danish drugmaker, to develop GUB014295, a potential weight loss therapy.Continue reading

Mar 10, 2025 - 13:04
 0
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales. That's why other drugmakers want to dip their toes in this lucrative and high-growth market.

AbbVie (NYSE: ABBV) is one of them. The company, best known for its work in immunology, recently made a move to enter the weight loss space. Does that make AbbVie stock a buy today?

Developing therapies from scratch is risky and time-consuming. That's why pharmaceutical giants often partner with small companies that already have candidates in early-stage studies -- it helps speed up the process from their perspective. AbbVie is doing just that to join the weight loss market. The company entered into an agreement with Gubra A/S, a Danish drugmaker, to develop GUB014295, a potential weight loss therapy.

Continue reading